Abstract
Introduction

Cyclin-dependent kinase subunit (cks)1* was initially identified in 1986 in fission yeast by virtue of its ability to rescue certain temperature sensitive mutants of fission yeast cyclin-dependent kinase (cdc2)
and further biochemical studies revealed its vital role in the regulation of cell division cycle [2] [3] . Its human homologue was identified in 1987 in complex with cdc2 [4] [5] .
Both fission yeast and budding yeast homologues show 67% amino acid sequence identity with a single difference being the presence of additional 16 consecutive glutamine codons in bud-
ding yeast cks1 gene [6] . cks1 and cks2 show 53% and 57% identity, respectively, with both budding yeast and fission yeast homologues [5] whereas the xenopus homologue of cks1 shows 91% identity with cks2 [7] . Expression analysis shows cks1 abundance throughout cell division cycle. It forms a complex with both partial (in absence of regulatory cyclins) and complete forms of cdc2 active kinase which is maintained even when the cells enter into stationary phase and during abnormal cell division states (S phase arrest) [6] [7] [8] .
*To bring more clarity and uniformity, the general names 'cks1' and 'cdc2' is used throughout the manuscript to represent all the cks1 and cdc2 homologues, respectively, in different species.
Functional analyses of cks1
The essential functions of cks1 for normal cell division and growth have been demonstrated through various genetic and biochemical experiments in different species. cks1 deletion confers mitotic arrest phenotype that eventually lose viability whereas its overexpression produced another abnormal phenotype due to delayed mitotic entry [2, 9, 10] . These observations and the demonstration that cks1 deleted fission yeast could enter mitosis [9] initially suggested the physiological requirement of cks1 exclusive for mitotic exit. However, conditional mutation and functional inactivation experiments have indicated the requirement of proper functions of cks1 for both G1/S and G2/M transitions and maintenance of cell viability [6, 11] . Interestingly, consistent with the production of abnormal mitotic phenotype, cks1 overexpression has induced abnormal effects in meiosis also (production of two spored asci which failed to complete second meiotic nuclear division) underscoring the pathological functions of cks1 when it is expressed at physiologically high levels [2, 10] . Thus, it is evident that cks1 functions at multiple levels, depending upon the cell division status, for normal check point transitions, mitotic progression and mitotic exit. Similarly, it is interesting to observe that both deletion and overexpression of cks1 could confer a similar phenotype (delayed mitotic entry) [6, 7, 11] Cell cycle kinetics depends upon changes in the kinase activity of cyclin-dependent kinases [12, 13] . The influence of cks1 on cell division cycle and its complex formation with mitotic cdks has thus put forth substantial hint for cks1 having critical roles in regulating the kinase activity of cdks. Substantiating this hypothesis, fission yeast studies demonstrated that only 5% of total cdc2, which is found to be in complex with cks1, is active as a kinase [8] . Similarly, cks1 association was observed in both partial and completely active cdc2 kinase complex in budding yeast [6] . Depletion of cks1 from xenopus egg interphase extract had a negative effect on cdc2 kinase activity to perform G2/M transition [7] . However, as in the case of cks1 depleted/overexpressed functional phenotypes, quite distinct observations were obvious. In particular, cks1 deleted cells arrest at M phase with high cdc2 kinase activity [7, 9, 11] . Furthermore, addition of exogenous cks1 to interphase extract had remarkably reduced cdc2 kinase activity and prevents mitotic entry [7] . A probable role of cks1 to inactivate cdc2 kinase activity has also been observed in fission yeast [9] . Overall [9, 14] had refocused the research on molecules that interacts with cks1, apart from cdc2, and the quest is still on to respond to the queries.
cks1: linking the unlinked
cdc2 is the sole kinase protein which mediates all stages of cell division in yeast [15] whereas in higher eukaryotes it is primarily engaged in mediating G2/M phase transition and mitotic progression [13, 16] . Under normal conditions, cdc2 is maintained inactive during interphase due to inhibitory phosphorylation at tyrosine 15 and threonine 14 residues by wee1 and myt1 kinases and cdc2 activation occurs after dephosphorylation of these residues by cdc25 phosphatase [17] [17, 18] . cdc25 becomes active upon phosphorylation whereas phosphorylation negatively regulates wee1/myt1 kinase activity [17] .
Molecular mechanistic studies show lack of Tyr 15 dephosphorylation in cks1-depleted interphase extract and this molecular defect correlates with the functional phenotype (lack of mitotic entry) observed in cks1 depleted cells [7] . This indeed indicates the requirement of cks1 activity for Tyr-15 dephosphorylation and correlates well with the role of cks1 in promoting MPF-dependent phosphorylation of cdc25, wee1 and myt1 [19] . Interestingly, addition of excess recombinant cks1 to interphase extract has also showed similar phenotype associated with lack of cdc25 phosphorylation and Tyr-15 dephosphorylation [7] . This reveals the optimum docking theory for cks1 wherein cks1 at normal levels may serve for the interaction/or acts as a docking factor between MPF and cdc25 or Wee1/Myt1 for eliciting normal cell cycle functions ( Fig. 1 ) and higher concentrations of cks1 may disrupt such an interaction [7] . Even [20] . Initially, it was interesting to observe that cks1 depleted mitotic extracts could accumulate cyclin B which was reversed upon addition of recombinant cks1 [7, 10] [22] and its association with active phosphorylated APC/C complex suggest it is through its interaction with APC/C [23] whereas another group claims that it is through its direct interaction with 19S proteasome components (Fig. 2) as demonstrated from a direct association of cks1 with 19S proteasome components (Rpn3, Rpt1 and Rpt6) [21] . Overall, because MPF-dependent phosphorylation functions of cks1 on wee1, myt1, cdc25, cdc27 and BIME requires less modification of MPF kinase activity, these results suggest cks1 as a master docking agent for the execution of proper cell cycle functions [19, 22, 24] . [24, 27] .
cks1 acts as a transcriptional regulator
Underscoring its mitotic functions, cks1 has been shown to be involved in the efficient transcription of cdc20 (activator of APC/C). This specific transcription is associated with physical recruitment of proteasome components (Rpt1, Pre1) to the cdc20 promoter region. Though, it remains unclear whether the proteolytic or non-proteolytic functions of proteasomes contribute to cdc20 transcription, the involvement of cks1 in recruiting proteasomes to this specific promoter region is well established. In addition, cks1 is also required for the periodic dissociation of cdc2 from the cdc20 promoter region for eliciting this specific transcription [25]. Therefore it is likely that, in addition to cyclin B degradation, cdc20 transcription is also involved in the basic mechanisms underlying cks1-dependent mitotic regulation. Adding up to its transcriptional roles, cks1-cdc2 complex stimulates GAL1 transcription by recruiting proteasome to the GALI ORF and there are studies (unpublished data) indicating the requirement of cks1 for the efficient transcription of approximately 25% of genes in the yeast genome [26]. Consistent with this, cks1 has been shown to regulate transcription of cdc2, cyclin B and cyclin A in mammalian cells
cks1 turnover
The possible pathological roles of cks1 in tumour progression have made it crucial to address its turnover mechanism. Its mRNA [5, 28] . In comparison, cks1 mRNA levels are low in early G1 cells and increases in G2 to M cells [5, 28, 29] [35, 36] . Recently, cyclin D1 and B-RAF-MEK signalling has been implicated in cks1 mRNA regulation [37] . [38] . While initial co-immunoprecipitation studies revealed cks1 interaction with cdc2, a major breakthrough occurred when cks1 crystal structure resolved in complex with cdk2 [39] . cks1 shows structural homology with N-lobe domain of human cdk2 which extends to the functionally important cdk2 ATP binding site [38] . Earlier, the association of cks1 with cdk2 was observed in xenopus but considered insignificant due to its already highly established mitotic functions [7] . The crystal structure of cks1/cdk2 complex showed the interaction of cks1 with cdk2 C-lobe and positioned it at an opposite side relative to the structurally homologous cdk2 N-lobe and placed 26A far from cdk2 Tyr-15. This binding site is entirely different from that of cyclin located predominantly in the cdk2 N-lobe.
kinetics reveal two peaks with a small one at G1 to S boundary and a larger one near the end of the cell cycle (G2/M phase)
Identification of the ubiquitin ligase involved in the ubiquitination of cks1 has gained considerable attention once it has been established that cks1 is degraded through
Structural basis for docking functions
The cdk2-cks1 crystal structure positions the cks1 anion binding site on the same side of the cdk2 catalytic site, thus forming an extended recognition surface flanking the cdk2 catalytic site. A conserved exposed surface is positioned adjacent to this anion binding site which could probably aid in cks1 binding to a second protein and implicates a structural basis for cks1 to enhance the interaction between cdk2 and its substrates and at least one other phosphoprotein (Fig. 3) [40] .
Targeting function of skp2-p27 interaction
Independent experiments from two different groups [41, 42] [43, 44] . The association of skp2 and cks1 has been observed long back in transformed human fibroblasts in complex form with cyclin A-cdk2, but the functional significance of such complex was unknown [45] . Further studies had demonstrated a direct interaction of skp2 and cks1 in mammalian cells [46] . Like in skp2 Ϫ/-murine cells, targeted deletion of cks1 also accumulates phosphorylated p27 in its non-ubiquitinated form [42] and several studies demonstrated that skp2-cks1 interaction is vital for p27 ubiquitination [41, 47] . [42, 48] and the adaptor model suggests cks1 to act as an adaptor linking skp2 and phospho-p27 and thereby facilitating the interaction [41, 49] . In addition the structural requirement of cyclin E/A-cdk2 complex is also suggested for this biological interaction [50] . Combining all these, a new model has been proposed by Sitry et ligase (Fig. 4) . [42] . Recently, cks1 has been shown to be required for cdk2-/cyclin E-dependent phosphorylation of skp2 in vitro which has a positive effect on skp2 auto ubiquitination [53] . However, this function of cks1 is limited to certain conditions as cks1 in presence of phosphorylated p27 has a negative effect on skp2 ubiquitination [35, 53] . This deviation might be due to p27 occupying skp2 in presence of cks1 and thereby hindering its ubiquitination. Also, at times of reduced cks1 levels, the inefficiency of p27 to occupy skp2 may prevent its antagonistic effect on skp2 ubiquitination and this may explain why cks1 downregulation most of the time accompanies skp2 down-regulation [27, 30, 37] .
Initially two models have been put forth to explain this interaction. The allosteric model suggests the induction of a conformational change in skp2 upon cks1 binding which facilitates phosphop27 access to skp2
Other targets of human cks1
There is strong evidence for cks1 control over cyclin B degradation in yeast and xenopus [7, 10, 21] . Based on this, regulatory effect of cks1 on cyclin B degradation has been studied in human fibroblasts at conditions of a transient block at M phase and hence observed to stimulate the same [28] . However, the exact molecular mechanism by which it stimulates cyclin B degradation in human system has not been identified yet. More recently, cyclin A degradation has been found to be promoted by human cks proteins [62] . 
Mitotic functions of human cks1
Although p27 ubiquitination has been identified as the key function of mammalian cks1 its possible mitotic functions has never been ruled out in light of the well-established mitotic roles of its homologues in lower eukaryotes. Crystal structure analysis shows that cks1 binds to continuous sequence of residues that forms ␣ helix 5 and loop L14 at the carboxy terminal lobe of the cdk2 which are evolutionarily conserved in a subset of human cdks: cdc2, cdk2 and cdk3 [63] . This indicates its possible association with human cdc2. A reminder at this point is mandatory that cks1 was initially identified in complex with mitotic cdc2 in HeLa cells [4] . In addition, cks1 was found to be present in cdc2-cyclin B immunoprecipitates from human fibroblasts [45] .
Determining 
Human cks1 and cancer
The importance of cks1 in cancer pathology is reflected from its overexpression in tumours that have poor prognosis. cks1 overexpression has been observed in prostate cancer [65] and combined overexpression of cks1 and skp2 has been observed in breast, oral, urothelial, colon, gastric and lung cancers [66] [67] [68] [69] [70] [71] . cks1 expression has been observed to be inversely correlated with p27 levels in some cancer biopsies [66, 67, 69, 70] whereas biopsies from other few cancer types showed no such correlation [68, 71] . This indicates that different mechanisms may be involved in cks1 mediated tumour initiation and progression.
Following the identification of cks1 as a growth stimulatory agent, in particular its regulatory role at G1/S transition, researchers have been keen in looking into its involvement in various small molecules'/drugs' pharmacology. Retinoic acid [72] , oncostatin M [73] and fluoxetine [74] [24, 27, 28, 62] and cdc2 kinase activity [64] , its implications in cancer progression has not been evaluated in clinical samples.
Another interesting question to be addressed is whether cks1 acts as a tumour initiator or enhances the tumour progression by acting as secondary tumour triggering agent for some primary disease cause. Crystal structure studies proposed the inefficiency of cks1 dimer conformation to form complex with cdk2 [39] . Because p27 ubiquitination requires cdk2-cks1 assembly and also proteasome-dependent cks1 turnover mainly occurs at M phase [30, 31] 
Similarities Dissimilarities
Presence of 815 identical amino acids revealing 81% identity in the amino acid sequence [5] cks1 is primarily monomeric whereas cks2 exists in monomeric, dimeric and hexameric forms [38] Phosphate and cdk2 binding surfaces of both cks1 and cks2 are similar and sequence conserved [49] cks2 does not bind to skp2 whereas cks1 binds [42] (this may be due to the replacement of Ser41 and Asn45, which participate in the extended hydrogen bond network, with glutamic acid and arginine residues, respectively, in cks2) [54] .
Both of them bind to cdc2 [5] cks2 knockout cells do not accumulate p27 whereas cks1 knock out cells do [42] Stable overexpressions of both of them promote polyploidy at conditions of transient spindle cell cycle arrest induced by colcemide [28] cks2 mRNA increases sevenfold in G2 to M phase cells compared to G1 cells whereas cks1 mRNA increases fourfold [5] Both of them degrade through proteasome machinery [31] p53 mutation does not elevate cks2 expression whereas it elevates cks1 expression [28] Combined deletion of both cks1 and cks2 leads to early embryonic lethality at or before the morula stage indicating some common essential functions for these two orthologues at this stage of development [24] cks2 is abundantly expressed in mature testes in mice and cks2 -/-mice are sterile whereas cks1 is not expressed in mature testis [79] Both of them are involved in promoting cyclin A degradation [62] [42, 76] . In addition, cks1 null cells retain viability with a slow proliferation rate [42, 77] . Though cks1 disruption up-regulates p27 and disrupts G2/M phase transition, this may not be ultimate for the induction of apoptosis. Interestingly, combined knockdown of both cks1 and cks2 conferred lethality in mouse embryo and induced apoptosis in HeLa cells [24] . More recently, an independent role of cks2 to protect cells from apoptosis has been demonstrated [65] . This indeed indicates that independent targeting of either cks1 or cks2 may be utilized in repairing the disrupted molecular mechanism associated with cell proliferation or apoptosis whereas combined targeting can be adopted to drive cytotoxicity in tumour cells. Interestingly, cks1 has now been presented as a unique model to study the molecular mechanism of poly (Q) aggregation associated with polyglutamine deposition diseases thus extending its biological importance beyond the horizon of cancer [78] .
